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Abstract  
Some perfluoroalkyl and polyfluoroalkyl substances (PFASs) have become widespread  
pollutants detected in human and wildlife samples worldwide.  The main objective of this  
study was to assess temporal trends of PFAS concentrations in human blood in Australia  
over the last decade (2002–2011), taking into consideration age and sex trends.  
  
Pooled human sera from 2002/03 (n=26); 2008/09 (n=24) and 2010/11 (n=24) from  
South East Queensland, Australia were obtained from de-identified surplus pathology  
samples and compared with samples collected previously from 2006/07 (n=84).  A total  
of 9775 samples in 158 pools were available for assessment of PFASs. Stratification  
criteria included sex and age: <16 years (2002/03 only); 0–4 (2006/07, 2008/09, 2010/11);  
5–15 (2006/07, 2008/09, 2010/11); 16–30; 31–45; 46–60; and >60 years (all collection  
periods). Sera were analyzed using on-line solid-phase extraction coupled to high-  
performance liquid chromatography-isotope dilution-tandem mass spectrometry.  
  
Perfluorooctane sulfonate (PFOS) was detected in the highest concentrations ranging  
from 5.3–19.2 ng/ml (2008/09) to 4.4–17.4 ng/ml (2010/11).  Perfluorooctanoate (PFOA)  
was detected in the next highest concentration ranging from 2.8–7.3 ng/ml (2008/09) to  
3.1–6.5 ng/ml (2010/11).  All other measured PFASs were detected at concentrations <1  
ng/ml with the exception of perfluorohexane sulfonate which ranged from 1.2–5.7 ng/ml  
(08/09) and 1.4–5.4 ng/ml (10/11).  The mean concentrations of both PFOS and PFOA in  
the 2010/11 period compared to 2002/03 were lower for all adult age groups by 56%.  For  
5-15 year olds, the decrease was 66% (PFOS) and 63% (PFOA) from 2002/03 to 2010/11.   
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For 0-4 year olds the decrease from 2006/07 (when data were first available for this age  
group) was 50% (PFOS) and 22% (PFOA).   
  
This study provides strong evidence for decreasing serum PFOS and PFOA  
concentrations in an Australian population from 2002 through 2011. Age trends were  
variable and concentrations were higher in males than females.  Global use has been in  
decline since around 2002 and hence primary exposure levels are expected to be  
decreasing. Further biomonitoring will allow assessment of PFAS exposures to confirm  
trends in exposure as primary and eventually secondary sources are depleted.        
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1.  Introduction  
Perfluoroalkyl and polyfluoroalkyl substances (PFASs) have entered the environment  
since the 1950s from fluoropolymer manufacturing processes and disposal of products  
containing fluorochemicals, such as carpet and apparel, pharmaceuticals, fire fighting  
foams, lubricants, adhesives, cosmetics, paper coatings, leather, pesticides and  
insecticides (Key et al. 1997; Prevedouros et al. 2006; Paul 2009).  Directly emitted  
PFASs are globally distributed and transported long distances via oceanic transport  
(Wania 2007; Armitage et al. 2009). Perfluorinated alkylated acids, one type of PFASs,  
including perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA), are also  
distributed through wet and dry deposition as a result of oxidative degradation processes  
in the atmosphere of volatile precursors, such as fluorotelomer alcohols, perfluorinated  
sulfonamide alcohols, fluorotelomer acrylates and fluorotelomer olefins (Ellis et al. 2003;  
Young and Mabury 2010).  
  
In recent years, PFOS and PFOA have been studied extensively due to their high  
resistance to both chemical and biological degradation as well as potential for  
bioaccumulation (Lau et al. 2007). As a consequence of their persistence and widespread  
usage, ubiquitous distribution in both environmental and human samples exists (e.g.  
Giesy and Kannan 2001; Kannan et al. 2004; Calafat et al. 2007; Kärrman et al. 2007).   
Because of its characteristics of toxicity, persistence, bioaccumulation and long range  
transport, PFOS was listed under the Stockholm Convention on Persistent Organic  
Pollutants in 2009 (Stockholm Convention on POPs 2010). Definitive health risks  
associated with PFAS exposure in humans have not been reported, with studies of  
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persons occupationally exposed to relatively high concentrations showing varying results  
(Olsen et al. 2003; Wang et al. 2012).  Similarly, epidemiological studies of PFASs and  
various endpoints have also shown varying results.  Several authors have reported  
associations between maternal PFAS concentrations and negative effects with regards to  
fetal development.  Fei et al. (2007) reported PFOA levels were inversely associated with  
birth weight; Apelberg et al. (2007) found negative associations between both PFOS and  
PFOA concentrations and birth weight and size; and Darrow et al. (2013) also found a  
negative association with PFOS and birth weight. Some studies have suggested  
associations between PFOS and PFOA serum concentrations and thyroid disease (Melzer  
et al. 2010); and alterations to lipid metabolism (Steenland et al. 2009).  Associations  
have been observed for perfluorohexane sulfonate (PFHxS) but not PFOA and PFOS  
with an elevated odds of high cholesterol, total cholesterol, low-density lipoprotein  
cholesterol, total cholesterol/high density lipoprotein (HDL) cholesterol ratio and non-  
HDL cholesterol (Fisher et al. 2013).  An assessment of potentially exposed persons in  
West Virginia, USA found among other results, probable links between PFOA exposure  
and diseases such as kidney and testicular cancer (Barry et al. 2013), thyroid disease  
(Winquist and Steenland 2014) high cholesterol, ulcerative colitis and pregnancy-induced  
hypertension (C8 Science Panel 2014).  
  
Human exposure to PFASs occurs via point sources such as manufacturing plants (Oliaei  
et al. 2013), food (Fromme et al. 2009; Clarke et al. 2010; Egeghy and Lorber 2011) and  
its packaging (Begley et al. 2005), drinking water (Eriksson et al. 2013), and household  
dust (Goosey and Harrad 2011; Fraser et al. 2013).  Both direct and indirect exposures  
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occur because PFOS and PFOA are stable degradation products/metabolites of other  
PFASs (Kato et al., 2011; Li et al., 2011).   
  
PFASs were first detected in Australian human blood serum collected in 2002-03 at  
concentrations equal to or higher than reported in Europe and Asia but lower than in the  
USA (Kärrman et al. 2006).  This finding was unexpected as concentrations of  
“traditional” persistent organic pollutants such as dioxins and polychlorinated biphenyls  
have been relatively low in Australia (Harden et al. 2007).    
  
The main objective of this study is to assess temporal trends of PFAS concentrations in  
Australia over the last decade (2002–2011).  Assessment of any temporal trends allows a  
gauge of the success of the increased regulatory scrutiny in recent years of PFAS in  
Australia.  It can also reflect changes in the pattern and extent of exposure in the  
Australian population following a global decrease in manufacture and emission of certain  
PFASs and potential increase in others due to shifts in production. In this study existing  
data on PFASs in blood from Australians in 2006/07 (Toms et al. 2009), archived  
samples from 2002/03, and newly collected samples from 2008/09 and 2010/11 will be  
used to evaluate whether global changes in PFAS usage have affected human exposure to  
these chemicals in Australia.    
   
2.  Materials and Methods:   
2.1  Sample collection  
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We used archived pooled human sera from 2002/03 (n=26) and samples collected in  
2008/09 (n=24 pools, 2400 individual samples) and 2010/11 (n=24 pools, 2400  
individual samples) from South East Queensland, Australia.  PFAS pooled sera  
concentrations from 2006/07 (n=84) were reported previously (Toms et al. 2009).  All  
samples were obtained in collaboration with Sullivan Nicolaides Pathology from de-  
identified surplus pathology samples.  That is, samples were collected from individuals in  
the community setting for assessment of biochemical parameters; the serum remaining  
after these assessments was surplus to requirement by the pathology clinic and made  
available for research purposes.  Stratification criteria included age: <16 years (02/03  
only); 0–4 (08/09, 10/11); 5–15 (08/09, 10/11); 16–30; 31–45; 46–60; and >60 years (all  
collection periods).  As reported and discussed in detail in Toms et al. (2009), the  
2006/07 samples were stratified as follows: 0–0.5; 0.6–1; 1.1–1.5; 1.6–2; 2.1–2.5; 2.6–3;  
3.1–3.5; 3.6–4; 4.1–6; 6.1–9; 9.1–12; 12.1–15 years. For comparative purposes, in this  
study these age brackets will be combined into 0–4 years or 5–15 years as appropriate for  
comparison with age groups from other collection periods.  Both males and females were  
included.  Each pool consisted of up to 100 samples (see Harden et al. 2007 for details),  
with the exception of the 2006/07 pools that consisted of approximately 30 samples (see  
Toms et al. 2009 for details).  It was not possible to determine if any one donor  
contributed to more than one collection period.  Ethics approval for this study was  
granted by The University of Queensland Medical Research Ethics Committee.  The  
involvement of investigators at the Centers for Disease Control and Prevention (CDC)  
was determined not to constitute engagement in human subjects research [45 CFR  
46.101(d)].    
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2.2  Measurement of PFASs in Serum  
All samples were analysed at the Division of Laboratory Sciences, National Center for  
Environmental Health, CDC, Atlanta, USA by a modification of the Kuklenyik et al.  
(2005) approach, involving on-line solid-phase extraction coupled to high-performance  
liquid chromatography-isotope dilution-tandem mass spectrometry (Calafat et al. 2007;  
Calafat et al. 2007). Limits of detection (LOD) were 0.2 ng/ml (2-(N-ethyl-  
perfluorooctanesulfonamido) acetate [Et-PFOSA-AcOH], 2-(N-methyl-  
perfluorooctanesulfonamido) acetate [Me-PFOSA-AcOH], perfluorodecanoate [PFDeA])  
and 0.1 ng/ml (PFHxS, perfluorononanoate [PFNA], PFOA, PFOS,  
perfluorooctanesulfonamide [PFOSA]) (Calafat et al. 2007).  Quality control/quality  
assurance (QC/QA) included sampling replication of pools for a given strata and analysis  
of blank samples.  CDC researchers received coded samples and were blind to the pools’  
characteristics.  Analytical standards, low- and high-concentration QC samples (prepared  
from spiked calf serum) and reagent blank samples were included in each analytical batch  
along with the study samples (Kuklenyik et al. 2005).   
  
Moreover, for the 2006/07, 2002/03 and 2008/09 pools, two, two and one samples of calf  
serum (Sigma Aldrich B8655), respectively, known to have concentrations of the target  
PFASs below the LOD, were aliquoted, pooled, stored, shipped and analyzed using  
identical procedures to human blood sera. No PFASs were detected in these blank  
samples. Sample replication between pools of the same strata (i.e., two pools which were  
obtained for the same age and sex) was assessed using the normalised difference ([a-  
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b]/([a+b]/2)) x 100 %) (where a is the value from Pool 1 and b is the value from Pool 2)  
and the average described as the mean normalised difference (MND) for all age groups  
and both sexes combined.  In 2008/09, the MNDs for PFOS and PFOA were 13% and  
10%, respectively and in 2010/11, the MNDs for PFOS and PFOA were 18% and 16%,  
respectively.  This agreement between replicates and absence of PFASs in the blank  
serum suggests that the pooling procedures were uniform and contamination during  
sampling or analysis was unlikely.   
  
2.3  Statistical analysis  
Statistical analysis was mainly descriptive to estimate average concentrations (means or  
medians as appropriate) and standard deviations or ranges. ANOVA models with the  
Tukey post test carried out using GraphPad Prism 5. The conventional 5% cut-off was  
used to report results as statistically significant. Concentrations <LOD were imputed a  
value of zero in the statistical analysis.  
  
3.  Results and Discussion  
PFASs were detected in all pools of human blood sera from all four collection periods.   
The PFASs detected in the highest concentrations were PFOS (total PFOS - linear plus  
branched structural isomers) which ranged from 5.3–19.2 ng/ml (2008/09) and 4.4–17.4  
ng/ml (2010/11).  PFOA was detected in the next highest concentration ranging from 2.8-  
7.3 ng/ml (2008/09) and 3.1–6.5 ng/ml (2010/11).  All other measured PFASs were  
detected at concentrations <1 ng/ml with the exception of PFHxS which ranged from 1.2–  
5.7 ng/ml (2008/09) and 1.4–5.4 ng/ml (2010/11).  All results for 2002/02, 2008/09 and  
11 
 
2010 are available in Supporting Information, Table S1, those for 2006/07 are available  
in Toms et al. (2009).  Temporal and international trends as well as age and sex trends are  
discussed below.   
  
3.1  Temporal trends  
Concentrations of PFASs determined in pools of human blood serum collected in  
Australia in 2002/03, 2006/07, 2008/09 and 2010/11 were compared to assess changes  
over time (Figures 1-2).  From the data obtained in this study, decreasing temporal trends  
were apparent from 2002/03 to 2010/11.  The mean concentrations of both PFOS and  
PFOA in the 2010/11 period compared to 2002/03 were lower for all adult age groups by  
56%.  For 5-15 year olds the decrease was 66% and 63% for PFOS and PFOA,  
respectively, from 2002/03 to 2010/11.  For 0-4 year olds the decrease from 2006/07  
(when data were first available for this age group) was 50% and 22% for PFOS and  
PFOA, respectively (Table 1). It is expected that exposure as evident from the  
concentrations in the 2010/11 pools, will be lower than in the early 2000s and will likely  
continue to decrease slowly. As exposure continues to decrease and elimination occurs,  
although at differing rates considering the varying human half-lives for PFASs (e.g., 4.8  
years [PFOS], 3.5 years [PFOA], (Olsen et al. 2007)), current PFAS sera concentrations  
will reflect the recent decreased exposure due to global changes in use.   
  
Trends in concentrations of the other PFAS should be interpreted with caution due to low  
detection rates and low concentrations.  Et-PFOSA-AcOH and Me-PFOSA-AcOH  
decreased 75% and 63% from 2002/03 to 2010/11 for 5-15 and >16 year olds,  
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respectively.  Concentrations of PFHxS increased 5% in the >16 years group but  
decreased 48% for the 5-15 year olds.  PFNA concentrations increased 51% and 19% for  
5-15 and >16 year olds, respectively.  PFDeA concentrations increased from below the  
limit of detection (0.1 ng/mL) in 2002/03 to 0.3 and 0.4 ng/ml for 5-15 and >16 year olds,  
respectively.  PFOSA was detected in only a few pools in 2002/03 and then not at all in  
2010/11.  
  
The ANOVA test results show the mean concentration difference is statistically  
significant between year of collection for PFOS (Figure 1) for 0-4 year olds (p=0.002), 5-  
15 year olds (p<0.0001) and >16 year olds (p<0.0001).  Tukey’s post test showed  
statistically significant differences between mean concentrations across collection periods  
(p<0.05) with the exception of 2008/09 and 2010/11 for all three age groupings.  For  
PFOA (Figure 2), the mean concentration difference was statistically significant between  
year of collection for 0-4 year olds (p=0.004), 5 – 15 year olds (p<0.0001) and > 16 years  
olds (p<0.0001) with the Tukey’s post test reaching significance for all collection periods  
except 2008/09 and 2010/11 for 0- 4 years olds and 5-15 year olds and 2006/07 and  
2008/09 for >16 year olds.   
  
These overall decreasing levels are in accordance with the voluntary phase out of  
perfluorooctanesulfonyl fluoride (PFOSF) based compounds by the 3M Company in the  
USA, which was completed in 2002 (3M, 2000).  In Australia, PFOS and PFOA have  
been imported and used as, among others, mist suppressants in the metal plating industry,  
hydraulic fluid in the aviation industry, surfactants in the photography industry and as  
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fire-fighting foams. While alternatives to PFOS are available for mist suppressants in the  
metal plating industry and for fire-fighting foams, some of these are still fluorinated.  
Accordingly, PFAS-based chemicals with no known suitable and less hazardous  
alternatives are still used mainly as mist suppressants in the metal plating industry,  
hydraulic fluid in the aviation industry, surfactants in the photography industry and as  
fire-fighting foams.  While importation of PFOS increased between 2006 and 2008, this  
was mostly for uses for which alternatives are not readily available and overall from 2006  
to 2008 PFOS stocks in Australia had decreased (NICNAS 2013). Furthermore, PFAS  
use has been discouraged by the National Industrial Chemical Notification and  
Assessment Scheme (NICNAS) in Australia with voluntary phase out agreements by  
Australian industries since 2000 resulting in a rapid decrease in the use of PFOS-related  
chemicals (NICNAS 2013).  However, old stock of PFOS- and PFAS-based products  
could still be found in Australia or be held by consumers and industrial users, although  
import of PFOA-containing polymers virtually ceased after NICNAS and industry co-  
regulatory activity (NICNAS 2013).  
  
PFOS is still produced in at least three countries, namely Germany, Italy and China  
(Oliaei et al. 2013). As a result, PFOS levels have fallen in many parts of the world, but  
have increased in others—most notably in China (Oliaei et al. 2013).  Also of importance  
is that both PFOS and PFOA are also distributed through wet and dry deposition as a  
result of oxidative degradation processes in the atmosphere of volatile precursors, such as  
fluorotelomer alcohols, perfluorinated sulfonamide alcohols, fluorotelomer acrylates and  
fluorotelomer olefins (Ellis et al. 2003; Young and Mabury 2010).  These changes are  
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likely the reasons for decreasing concentrations of PFASs in human blood serum, but  
exposure to PFAS likely continues.  
  
In addition to overall concentrations, detection frequency changed over the 9 year  
sampling period but only for Et-PFOSA-AcOH, Me-PFOSA-AcOH, PFDeA and PFOSA.   
Et-PFOSA-ACOH and PFOSA decreased in detection frequency at 100%, 1%, 0% and 0%  
and 19%, 24%, 0% and 0% from 2002/03, 2006/07, 2008/09 and 2010/11, respectively  
(Table 2).  Me-PFOSA-AcOH, PFHxS, PFNA, PFOA and PFOS were detected  
consistently at or close to 100% across all periods.   The detection frequency of PFDeA  
increased from 0%, 90%, 88% and 100% from 2002/03, 2006/07, 2008/09 and 2010/11,  
respectively, but mean concentrations from 2006/07 through 2010/11 remained the same.   
This change in exposure scenario may be influenced by an onset of production of  
different homologues and relocation of manufacturing activities resulting in different  
exposure to the Australian population.  Analytical reasons are unlikely as the LODs did  
not change and the 2002/03 pools were analyzed at the same time as the 2008/09 pools.  
  
3.2  Age and sex trends  
Concentrations of PFOS, PFOA PFNA and PFHxS appeared to be higher in males than in  
females across all adult ages.  In the younger age groups, in particular, 0-4 and 5-15 years  
in 2008/09, concentrations were higher in the females compared to males and then a shift  
occurred around 16 years and concentrations in males were higher than in females.  The  
greatest difference was seen in the 30–45 and 46–60 year old persons then a stabilization  
occurred in the >60 years adults, with similar concentrations in both males and females.   
Sex differences in concentrations of PFDeA, Me-PFOSA-AcOH and Et-PFOSA-AcOH  
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were not obvious, although this may be attributable to the low detection of these  
chemicals.  Differences in exposure and/or pharmacokinetic reasons have been suggested  
for sex differences in PFAS concentrations (Calafat et al. 2007) although these are yet to  
be completely elucidated.  Lactation and pregnancy (So et al. 2006; Fei et al. 2007;  
Kärrman et al. 2007; Tao et al. 2008) result in the reduction of adult female PFAS body  
burden and menstruation has been investigated as an elimination route for pre-  
menopausal females (Harada et al. 2005; Knox et al. 2011; Taylor et al. 2014).   
Thompson et al. (2010) hypothesized that if blood loss via menstruation was the  
predominant reason for the observed differences in male and female serum PFAS  
concentrations, then the concentrations in males who are regular blood donors should be  
similar to those in typical pre-menopausal females. In fact, PFOS and PFOA  
concentrations in Australian males who regularly donated blood were almost half the  
concentration in males from the general population in Australia and much closer to  
concentrations in females (Thompson et al 2010), thus supporting the hypothesis of blood  
loss contributing to lower PFAS concentrations in human serum.  
  
There were varying patterns of PFAS concentrations by age in these Australian pools  
(Figure S1, Supporting Information).  PFAS concentrations appeared to increase from  
birth with the maximum concentrations of all PFASs detected in children <15 years with  
the exception of PFOS where concentrations increased with age peaking at  >60 years.   
Interestingly, a comparison of the data from samples collected in 2002/03 with those  
collected in 2008/09 and 2010/11 showed some differences in the age trend.  For example,  
for PFOS no clear age trend was observed in the 2002/03 samples whereas the  
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concentrations clearly increased with age in the 2010/11 samples.  For PFOA, we  
observed a decrease from the youngest age towards older age groups in the 2002/03 data  
whereas no decrease was observable in the recently collected samples.  It could be that  
these differences likely reflect a more rapid response to changing exposure concentrations  
in younger age groups which results in changing age trends.  The age trend in the most  
recently collected samples may reflect that older persons were more exposed than  
younger people when PFOS/PFOA were used/manufactured/imported and what is seen  
now is driven mainly by the elimination half-lives of these compounds. In 2002/03, in  
addition to elimination, concurrent exposure occurred and an age trend was harder to  
observe.   
  
3.3  International comparisons and temporal trends in human samples  
When compared to results from elsewhere, concentrations of PFOS and PFOA from  
2010/11 in Australia are similar or higher.  Concentrations are more than 6 and 2 times  
higher for PFOS and PFOA, respectively, than found in adults from Henan, an  
agricultural province in China (Fu et al. 2014), but similar to slightly higher in pregnant  
women from Tianjin, China (Jiang et al. 2014).  Concentrations in Australian females of  
child-bearing age (16-30 and 31-45 years) are more than and almost twice (PFOS and  
PFOA, respectively) that found in pregnant women from Germany (Fromme et al. 2010).   
PFOS and PFOA concentrations are 1.5 and twice those found in adults from the USA  
(Olsen et al. 2012).  
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A number of studies have been published examining temporal trends in human serum.    
Archived samples from Korea showed little variation in PFOS concentrations measured  
at three time points (1994, 2000, 2008) in Busan, and two points in Seoul (1994, 2007).   
However, PFOA concentrations appeared to increase in Seoul (Harada et al. 2010).  The  
same study reported a significant decrease in PFOA concentrations in Osaka Japan, when  
measured in 2004 and 2008.  However no significant differences were seen in two other  
Japanese cities.  Temporal trends from 2003 to 2011 were observed in serum from  
pregnant women in Hokkaido, Japan with a decline in PFOS and PFOA at 8.4%/year and  
3.1%/year, respectively, while concentrations of PFNA and perfluorodecanoate (PFDA)  
increased 4.7%/year and 2.4%/year, respectively (Okada et al. 2013).  In the USA,  
comparison of blood samples from adults collected in 2000-2001 with samples collected  
in 2010 show a 76% and 48% decrease in PFOS and PFOA concentrations, respectively  
(Olsen et al. 2012).  The more rapid decrease in PFOS was suggested as resulting from  
the 3M phaseout of PFOSF production (Olsen et al. 2008).    In 2006, the US  
Environment Protection Agency, along with eight major companies launched a PFOA  
Stewardship Program, in which companies committed to reduce global facility emissions  
and product content of PFOA and related chemicals by 95 per cent by 2010, and to work  
toward eliminating emissions and product content by 2015 (USEPA 2013).  Similarly  
comparing results from the National Health and Nutrition Examination Survey, an  
investigation of the health of about 5000 people every year, over several years points to  
an overall decrease in the US general population exposure to some PFASs (Calafat et al.  
2006; Calafat et al. 2007; Calafat et al. 2007).  Recently, Kato et al. (2011) reported  
decreasing trends for PFOS (1999/2000 to 2008) and PFHxS (1999 to 2006), but PFNA  
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had an increasing trend and PFOA remained stable from 2003 to 2008.  In males in  
Norway, concentrations of PFOS and PFOA decreased 26% and 23%, respectively from  
2001 to 2007 while PFHxS increased from 1979 to 2001 but not between 2001-2007.   
Concentrations of PFNA and PFDA increased from 1979 to 2007 (Nøst et al. 2014).  In  
Germany, trends were assessed from 1982 to 2010 with overall downward trend for  
PFOS, PFOA and PFHxS with no trends observable for PFNA (Schroter-Kermani et al.  
2013).   
  
Both the human and environmental studies present mixed conclusions on temporal trends  
of PFAS concentrations, and clearly point to a situation whereby local concentrations are  
influenced by production sources nearby.  In some cases the increase in PFOA and other  
PFASs may reflect the increased use of telomeric compounds relative to PFOSF based  
ones.  Worldwide, human and environmental concentrations of PFOS are decreasing in  
response to a decreased global production, however, exposure will continue via PFAS-  
containing products that will remain in circulation long after actual manufacture ceases.   
  
4.  Conclusions  
This study provides strong evidence for decreasing serum PFOS and PFOA  
concentrations in an Australian general population from 2002 through 2011.  By  
extension this suggests background levels of these compounds in Australia are also  
decreasing.  Taken together, these findings may be reflective of the recent global  
production changes, as well manufacturers’ and regulatory bodies’ efforts to limit  
emissions to the environment.  Further monitoring of the Australian population’s  
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concentrations of PFAS will allow assessment of PFAS exposures as primary and  
secondary stocks are depleted and exposure decreases further.        
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Table 1. Mean concentrations (ng/ml serum) of PFOS and PFOA by age group (years) and year of collection with percent  
difference to 2002/03 in brackets.  
Age group 
(years) 2002/03 2006/07** 2008/09 2010/11 
  PFOS PFOA PFOS PFOA PFOS PFOA PFOS PFOA 
0-4    
 
11.4 6.7 6 5.1 
5.7 
(50%*) 
5.2 
(22%*) 
5-15 (<16 - 
2002/03) 23.6 12 17 (28%) 6.6 (45%) 9.1 (61%) 4.8 (60%) 8 (66%) 4.5 (63%) 
>16 27 9.7 20.5 (24%) 6.2 (36%) 14.1 (48%) 5.3 (45%) 12 (56%) 4.3 (56%) 
* 2010/11 compared to 2006/07; ** data from Toms et al. (2009)  
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Table 2.  Summary results of PFAS concentrations (ng/mL) from 2002/03 (26 pools), 2006/07 (84 pools), 2008/09 (24 pools) and  
2010/11 (24 pools) of human blood serum, all ages and both sexes combined.  
Collection 
period 
PFC Frequency of 
detection* 
Range Mean Standard deviation Median 
2002/03 Et-PFOSA-AcOH 100% 0.3-0.8 0.5 0.1 0.5 
2006/07  1% <LOD – 0.2 n/a n/a n/a 
2008/09  0% n/a n/a n/a n/a 
2010/11  0% n/a n/a n/a n/a 
2002/03 Me-PFOSA-
AcOH 
100% 0.5 - 1.6 0.9 0.3 1.2 
2006/07  94% <LOD – 2 0.7 0.4 0.6 
2008/09  83% <LOD – 0.5 0.3 0.2 0.3 
2010/11  100% 0.1 - 0.5 0.3 0.1 0.2 
2002/03 PFDeA 0% n/a n/a n/a n/a 
2006/07  90% <LOD – 0.8 0.3 0.1 0.3 
2008/09  88% <LOD - 0.4 0.3 0.1 0.3 
2010/11  100% 0.2 - 0.4 0.3 0.1 0.3 
2002/03 PFHxS 100% 2 - 12.8 4.3 2.7 3.6 
2006/07  95% <LOD – 11.3 3.1 2 2.9 
2008/09  100% 1.2 - 5.7 2.9 1 3 
2010/11  100% 1.4 - 5.4 3.3 1 3.3 
2002/03 PFNA 100% 0.4 - 0.7 0.5 0.09 0.5 
2006/07  100% 0.1 - 1.4 0.8 0.3 0.8 
2008/09  100% 0.9 - 1.6 1.2 0.2 1.2 
2010/11  100% 0.6 - 0.9 0.7 0.1 0.8 
2002/03 PFOA 100% 7 - 14.5 10.2 1.7 10.6 
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2006/07  100% 0.8 - 9.1 6.4 1.5 6.4 
2008/09  100% 2.8 - 7.3 5.2 1 5.1 
2010/11  100% 3.1 - 6.5 4.5 0.8 4.3 
2002/03 PFOS 100% 19.1 - 36.1 25.9 4.7 25.4 
2006/07  100% 5 - 28.5 15.2 4.9 14.8 
2008/09  100% 5.3 - 19.2  11.9 4.6 11 
2010/11  100% 4.4 - 17.4 10.2 3.7 9.4 
2002/03 PFOSA 19% <LOD – 0.5 <LOD n/a n/a 
2006/07  24% <LOD – 0.5 0.4 0.1 0.1 
2008/09  0% n/a n/a n/a n/a 
2010/11  0% n/a n/a n/a n/a 
  
*The limits of detection (LOD) were 0.2 ng/ml (Et-PFOSA-AcOH – 2-(N-ethyl-perfluorooctane sulfonamido) acetate; Me-PFOSA-AcOH – 2-(N-methyl-  
perfluorooctane sulfonamido) acetate; PFDeA – perfluorodecanoate) and 0.1 ng/ml (PFHxS - perfluorohexane sulfonate; PFNA – perfluorononanoate; PFOA –  
perfluorooctanoate; PFOS - perfluorooctane sulfonate; PFOSA – perfluorooctane sulfonamide)  
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A    B   C   
Figure 1.  Box and whisker plot with median, minimum, maximum, 25th and 75th  
percentiles data for PFOA combined by sex and age (0-4 years A; <16 (5-15) years B)  
and >16 years C) by collection date. Note: 0-4 years not available from 2002/03  
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  A    B    C  
Figure 2. Box and whisker plot with median, minimum, maximum, 25th and 75th  
percentiles data for PFOS combined by sex and age  (0-4 years A; <16 (5-15) years B)  
and >16 years C) by collection date. Note: 0-4 years not available from 2002/03  
  
30 
 
  
   
31 
 
  
